Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma.
We report the case of a 52-yr-old man with metastatic lung adenocarcinoma who developed tumor lysis syndrome after administration of zoledronic acid. Tumor lysis syndrome in solid tumors and the antitumor effect of the zolendronic acid are discussed in light of the pertinent literature.
Kurt
Mevlut
M
Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Onal
Ibrahim K
IK
Elkiran
Tamer
T
Altun
Bulent
B
Altundag
Kadri
K
Gullu
Ibrahim
I
D000208:Acute Disease; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D015275:Tumor Lysis Syndrome / Q000097:blood / Q000175:diagnosis / Q000209:etiology*; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid